Dr Tim Wright, global head of development at Novartis Pharmaceuticals, said the company planned to continue to expedite its clinical trial program to build the supporting body of evidence for serelaxin per the FDA's advice.
written on 16.05.2014
Dr Tim Wright, global head of development at Novartis Pharmaceuticals, said the company planned to continue to expedite its clinical trial program to build the supporting body of evidence for serelaxin per the FDA's advice.
See our Cookie Privacy Policy Here